Mobile Origins, a TTP Firm targeted on enabling scalable, cost-effective and environment friendly manufacture of cell and gene therapies (CGTs), has immediately introduced the formation of its Advisory Board with the appointment of 4 globally recognised leaders throughout the cell and gene remedy (CGT) and robotics sectors — Professor John Campbell, Dr Matthew Li, Dr Paul Roberts, and Geoffrey Hodge. The newly fashioned Advisory Board will present a various vary of scientific, technical and strategic insights to help Mobile Origins’ progress because it continues to develop its robotic platform for the scalable and cost-effective manufacture of superior therapies, Constellation™.
Professor John Campbell is the co-founder of a number of cell remedy startups, together with Decision Therapeutics and Swarm Oncology. He brings over 30 years’ expertise within the immunology and cell remedy house, with important experience in course of growth and cell remedy manufacture. John was previously the Director of Tissues, Cells and Superior Therapeutics and Nationwide Head of Analysis on the Scottish Nationwide Blood Transfusion Service in Edinburgh.
Dr Matthew Li has labored within the tutorial and industrial biotech fields for over 14 years, with a give attention to gadgets, CGT R&D, and manufacturing. In his present position as Director, Cell Remedy CMC at Tome Biosciences, in addition to beforehand at Takeda and Vor Biopharma, Matthew has been intimately concerned within the due diligence, evaluation, and product growth of quite a few rising CGT manufacturing applied sciences.
Dr Paul Roberts is the co-founder of CMR Surgical, the place his crew developed robotic applied sciences enabling affected person entry to minimally invasive surgical procedure. Paul has intensive expertise in bringing robotics expertise to market in newly regulated environments, having offered key management in elevating the biggest ever MedTech non-public financing spherical with CMR Surgical in 2021. Previous to this, Paul led and grew capabilities in advanced medical machine growth on the Science Group Plc.
Geoffrey Hodge was most not too long ago CEO of SOTIO Biotech US and CTO of Unum Therapeutics, each autologous cell remedy firms. Previous to cell remedy, Geoff was the co-founder of Xcellerex, the place he was the first inventor of the XDR single-use bioreactor and head of the CDMO biomanufacturing providers enterprise, which grew to $50M in income previous to its acquisition by GE Healthcare.
Dr Edwin Stone, CEO of Mobile Origins, commented: “We’re trying ahead to working intently with John, Matthew, Paul and Geoff. While the challenges of the cell remedy business faces are distinctive, there is a gigantic quantity to be gained by ensuring we incorporate each the teachings from the journey the sphere has been on thus far, and the teachings which were realized in different industries. I’m excited by the breadth of expertise they’ve, having distinctive information and expertise that I’m assured will likely be invaluable to the Mobile Origins’ mission to develop scalable and cost-effective robotic expertise for the automated manufacture of superior therapies.”
Professor John Campbell, Advisor for Mobile Origins, stated: “Mobile Origins gives a transformative resolution for scalable cell remedy manufacture with their revolutionary robotic platform, Constellation. I stay up for becoming a member of the crew as a part of the Advisory Board, the place my very own expertise and that of my colleagues on the board will help Mobile Origins by means of this thrilling time of their growth and progress.”
